X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs PLETHICO PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA PLETHICO PHARMA TORRENT PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 27.2 -1.1 - View Chart
P/BV x 5.2 0.0 30,905.4% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 TORRENT PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
PLETHICO PHARMA
Mar-14
TORRENT PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,768395 447.7%   
Low Rs1,18631 3,787.9%   
Sales per share (Unadj.) Rs346.1604.4 57.3%  
Earnings per share (Unadj.) Rs55.232.5 169.9%  
Cash flow per share (Unadj.) Rs73.351.3 142.8%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs257.1473.6 54.3%  
Shares outstanding (eoy) m169.2234.08 496.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.30.4 1,210.1%   
Avg P/E ratio x26.86.6 408.0%  
P/CF ratio (eoy) x20.14.2 485.2%  
Price / Book Value ratio x5.70.5 1,276.5%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m249,8877,262 3,440.8%   
No. of employees `00011.8NA-   
Total wages/salary Rs m9,9341,596 622.4%   
Avg. sales/employee Rs Th4,971.5NM-  
Avg. wages/employee Rs Th843.2NM-  
Avg. net profit/employee Rs Th792.4NM-  
INCOME DATA
Net Sales Rs m58,56920,598 284.3%  
Other income Rs m2,233386 578.0%   
Total revenues Rs m60,80220,984 289.8%   
Gross profit Rs m13,7732,818 488.8%  
Depreciation Rs m3,069642 477.8%   
Interest Rs m2,0561,593 129.0%   
Profit before tax Rs m10,881969 1,123.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545-138 -1,116.6%   
Profit after tax Rs m9,3361,107 843.4%  
Gross profit margin %23.513.7 171.9%  
Effective tax rate %14.2-14.3 -99.4%   
Net profit margin %15.95.4 296.6%  
BALANCE SHEET DATA
Current assets Rs m53,84118,877 285.2%   
Current liabilities Rs m31,61211,896 265.7%   
Net working cap to sales %38.033.9 112.0%  
Current ratio x1.71.6 107.3%  
Inventory Days Days9736 270.4%  
Debtors Days Days84198 42.3%  
Net fixed assets Rs m42,0799,861 426.7%   
Share capital Rs m846341 248.4%   
"Free" reserves Rs m42,65512,331 345.9%   
Net worth Rs m43,50116,139 269.5%   
Long term debt Rs m22,4084,706 476.2%   
Total assets Rs m101,25033,146 305.5%  
Interest coverage x6.31.6 391.4%   
Debt to equity ratio x0.50.3 176.7%  
Sales to assets ratio x0.60.6 93.1%   
Return on assets %11.38.1 138.1%  
Return on equity %21.56.9 312.9%  
Return on capital %19.612.3 159.7%  
Exports to sales %021.4 0.0%   
Imports to sales %015.2 0.0%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs mNA3,136 0.0%   
Fx inflow Rs m20,0664,402 455.8%   
Fx outflow Rs m5,3043,184 166.6%   
Net fx Rs m14,7621,219 1,211.5%   
CASH FLOW
From Operations Rs m10,1272,437 415.5%  
From Investments Rs m-7,869-6,265 125.6%  
From Financial Activity Rs m-1,9182,490 -77.0%  
Net Cashflow Rs m212-1,337 -15.8%  

Share Holding

Indian Promoters % 71.5 82.7 86.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 4.3 163.3%  
FIIs % 12.6 5.5 229.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 7.5 117.3%  
Shareholders   26,511 10,665 248.6%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS